Apixaban API was developed at Minakem’s Canadian facility (Delmar Chemicals Inc.) in 2016. Apixaban API CAS number is 503612-47-3
From a regulatory perspective, Minakem offers:
Minakem’s Apixaban API brings:
Apixaban API is an anticoagulant that was approved under the trade name Eliquis in Europe in 2011 and in the United States in 2012.
It functions by inhibiting Factor Xa, which reduces thrombin generation and helps prevent the formation of blood clots (thrombus).
It leads to an effective anticoagulation without directly affecting platelet aggregation.
Minakem Montreal (Delmar chemicals Inc.) has been manufacturing Active Pharmaceutical Ingredients (APIs) since 1941.
It is the largest API facility in Canada, benefiting from a strong scientific and technological environment.
Located close to its U.S. customers in the New Jersey and Boston areas, Montreal also has a strong tradition of serving the entire North American market, as well as Latin America, Europe, Japan, China, and India.
Minakem Montreal collaborates daily with Minakem’s other European facilities, leveraging their complementary expertises in solid engineering, analytics, global regulatory affairs, and other capabilities to enhance competitiveness.
Minakem brings over 40 years of experience in developing, scaling up, registering Drug Master Files (DMFs), and manufacturing complex Active Pharmaceutical Ingredients (APIs), including chiral small molecules, steroids, and highly potent APIs (HPAPIs)—primarily used in oncology treatments.
As supply chain performance becomes increasingly critical to customers’ success, Minakem focuses on delivering:
Apixaban API’s data are available on
PharmaofferApixaban API additional data are available on
Wikipedia